VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

被引：43

作者：

Carbone, David P. ^{[1
]}

Salmon, J. Stuart ^{[3
]}

Billheimer, Dean ^{[2
]}

Chen, Heidi ^{[1
]}

Sandler, Alan ^{[1
]}

Roder, Heinrich ^{[4
]}

Roder, Joanna ^{[4
]}

Tsypin, Maxim

Herbst, Roy S. ^{[5
]}

Tsao, Anne S. ^{[5
]}

Tran, Hai T. ^{[5
]}

Dang, Thao P. ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA

[2] Univ Utah, Salt Lake City, UT USA

[3] Carolinas Hematol Oncol Associates, Charlotte, NC USA

[4] Biodesix, Steamboat Springs, CO USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

LUNG CANCER | 2010年 / 69卷 / 03期

关键词：

Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy; ENDOTHELIAL GROWTH-FACTOR; MASS-SPECTROMETRY; CHEMOTHERAPY; COMBINATION; RECURRENT;

D O I：

10.1016/j.lungcan.2009.11.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

引用

页码：337 / 340

页数：4

共 10 条

[1] Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials [J].

Douillard, Jean-Yves ;

Laporte, Silvy ;

Fossella, Frank ;

Georgoulias, Vassilis ;

Pujol, Jean-Louis ;

Kubota, Kaoru ;

Monnier, Alain ;

Kudoh, Shinzoh ;

Rubio, Jaime Ernesto ;

Cucherat, Michel .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) :939-946

[2] Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an eastern cooperative oncology group study [J].

Dowlati, Afshin ;

Gray, Robert ;

Sandler, Alan B. ;

Schiller, Joan H. ;

Johnson, David H. .

CLINICAL CANCER RESEARCH, 2008, 14 (05) :1407-1412

[3] Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer [J].

Herbst, Roy S. ;

O'Neill, Vincent J. ;

Fehrenbacher, Louis ;

Belani, Chandra P. ;

Bonomi, Philip D. ;

Hart, Lowell ;

Melnyk, Ostap ;

Ramies, David ;

Lin, Ming ;

Sandler, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4743-4750

[4] Angiogenesis and lung cancer: Prognostic and therapeutic implications [J].

Herbst, RS ;

Onn, A ;

Sandler, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3243-3256

[5] Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer [J].

Herbst, RS ;

Johnson, DH ;

Mininberg, E ;

Carbone, DP ;

Henderson, T ;

Kim, ES ;

Blumenschein, G ;

Lee, JJ ;

Liu, DD ;

Truong, MT ;

Hong, WK ;

Tran, H ;

Tsao, A ;

Xie, D ;

Ramies, DA ;

Mass, R ;

Seshagiri, S ;

Eberhard, DA ;

Kelley, SK ;

Sandler, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2544-2555

[6] Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen [J].

Salmon, Stuart ;

Chen, Heidi ;

Chen, Shuo ;

Herbst, Roy ;

Tsao, Anne ;

Tran, Hai ;

Sandler, Alan ;

Billheimer, Dean ;

Shyr, Yu ;

Lee, Ju-Whei ;

Massion, Pierre ;

Brahmer, Julie ;

Schiller, Joan ;

Carbone, David ;

Dang, Thao P. .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (06) :689-696

[7] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[8] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[9] Bevacizumab in the treatment of non-small-cell lung cancer [J].

Stinchcombe, T. E. ;

Socinski, M. A. .

ONCOGENE, 2007, 26 (25) :3691-3698

[10] Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study [J].

Taguchi, Fumiko ;

Solomon, Benjamin ;

Gregorc, Vanesa ;

Roder, Heinrich ;

Gray, Robert ;

Kasahara, Kazuo ;

Nishio, Makoto ;

Brahmer, Julie ;

Spreafico, Anna ;

Ludovini, Vienna ;

Massion, Pierre P. ;

Dziadziuszko, Rafal ;

Schiller, Joan ;

Grigorieva, Julia ;

Tsypin, Maxim ;

Hunsucker, Stephen W. ;

Caprioli, Richard ;

Duncan, Mark W. ;

Hirsch, Fred R. ;

Bunn, Paul A., Jr. ;

Carbone, David P. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :838-846

← 1 →